In this issue:
Effects of TDF ± GS-4774 therapy on HBV-specific T-cells
PROs during and after DAAs for chronic HCV
HCC incidence & outcomes in New Zealand: 1998–2017
Suboptimal real-life testing uptake for HBV & HCV
Chronic HCV infection: a significant issue in MSM
DAA regimens achieve SVR12 in HCV/HIV coinfection
Real-world SOF/VEL/VOX data from DAA-experienced HCV patients
Injection drug use contributes to risk for HCV epidemics
DAAs for chronic HCV safe in patients with prior HCC
Treat people with HCV who continue to inject drugs
Please login below to download this issue (PDF)